Consistent with responses in RCC to checkpoint blockade therapy and the role of CTLA4 in inhibiting CD28 signaling, a large portion of RCC CD8+ TILs had greatly elevated markers of activation and functional capacity when activated through the T cell receptor together with CD28 costimulation. This evidence concerns the gene CTLA4 and renal cell carcinoma.